z-logo
Premium
Comparing hypoxia‐targeting potential of 99m Tc(CO) 3 ‐labeled 2‐nitro and 4‐nitroimidazole
Author(s) -
Mallia Madhava B,
Subramanian Suresh,
Mathur Anupam,
Sarma H.D.,
Venkatesh Meera,
Banerjee Sharmila
Publication year - 2008
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.1525
Subject(s) - nitroimidazole , chemistry , iminodiacetic acid , misonidazole , biodistribution , bifunctional , nitro , hypoxia (environmental) , technetium 99m , radiochemistry , stereochemistry , chelation , nuclear chemistry , oxygen , nuclear medicine , organic chemistry , biochemistry , scintigraphy , catalysis , alkyl , in vitro , medicine
Non‐invasive determination of hypoxia is an important problem in clinical nuclear medicine. Although 18 F‐fluoromisonidazole is used clinically for hypoxia determination, the short half‐life ( t 1/2 =109.77 min), high cost and less availability of cyclotrone‐produced 18 F make 99m Tc ( t 1/2 =6 h)‐based agents more desirable. With this aim, 99m Tc(CO) 3 ‐labeled iminodiacetic acid derivatives of 2‐ and 4‐nitroimidazole are investigated for their ability to target hypoxic tumors. A bifunctional chelating agent, N , N ‐bis[(tert‐butoxycarbonyl)methyl]‐2‐bromoethylamine, was synthesized in the first step, which was then conjugated to the nitroimidazoles in the second step. The tert‐butyl ester derivatives formed were hydrolyzed to obtain the iminodiacetic acid derivatives of corresponding nitroimidazoles. The radiolabeling of the iminodiacetic acid derivatives with [ 99m Tc(CO) 3 (H 2 O) 3 ] + core was carried out following a reported protocol. Biodistribution of the prepared complexes was carried out in Swiss mice bearing fibrosarcoma tumor. The 2‐nitroimidazole complex showed a steady retention in activity (∼1.5% injected dose per gram [%ID/g]) in tumor throughout the period of study (3 h) indicating that it may be localized in the hypoxic cells. The 4‐nitroimidazole counterpart, however, showed an initial uptake of ∼4.6%ID/g at 30 min post injection, which was then observed to wash out rapidly. Copyright © 2008 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here